FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of August 2008
Commission File No. 000-30752
AETERNA ZENTARIS INC.
-------------------------------------
1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F /X/ Form 40-F / /
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes / / No /X/
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-____
DOCUMENTS INDEX
DOCUMENTS DESCRIPTION
1. Press Release dated August 6, 2008: AEterna Zentaris to Announce Second
Quarter 2008 Financial and Operating Results on August 12, 2008
[AETERNA ZENTARIS LOGO]
AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aezsinc.com
PRESS RELEASE
For immediate release
AETERNA ZENTARIS TO ANNOUNCE SECOND QUARTER 2008 FINANCIAL AND OPERATING RESULTS
ON AUGUST 12, 2008
QUEBEC CITY, CANADA, AUGUST 6, 2008 - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX:
AEZ), a global biopharmaceutical company focused on endocrine therapy and
oncology, will announce its second quarter 2008 financial and operating results
after market close on Tuesday, August 12, 2008. The Company will host a
conference call and webcast to discuss these results later that same day at 4:30
p.m., Eastern Time.
Participants may access the conference call by dialing the following numbers:
416-644-3430, 514-807-8791 or 800-814-4862. They may also access the live
webcast via the Company's website at www.aezsinc.com in the "Investors" section.
A replay of the webcast will also be available on the Company's website for a
period of 30 days.
ABOUT AETERNA ZENTARIS INC.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine
therapy and oncology with proven expertise in drug discovery, development and
commercialization. News releases and additional information are available at
www.aezsinc.com.
INVESTOR RELATIONS
Dennis Turpin, CA
Senior Vice President and Chief Financial Officer
(908) 626-5503
dturpin@aezsinc.com
MEDIA RELATIONS
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com
-30-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AETERNA ZENTARIS INC.
Date: August 6, 2008 By: /s/ Dennis Turpin
--------------------- ----------------------------------------------
Dennis Turpin
Senior Vice President, Chief Financial Officer